Last updated: February 19, 2026
What is the scope of patent MX2019003733?
Mexico patent MX2019003733 pertains to a pharmaceutical composition for the treatment of a specific medical condition, likely related to the targeted delivery or formulation of an active pharmaceutical ingredient (API). The scope is defined by its claims, which specify the composition, dosage form, and method of use.
The patent claims a novel combination of active compounds, potentially including a proprietary excipient or a unique formulation method intended to improve bioavailability or stability. The claims cover:
- A pharmaceutical formulation comprising an API and a specific excipient or carrier material.
- A method of preparing the formulation involving particular mixing or processing steps.
- Use of the formulation for treatment of a specified condition, for example, a metabolic disorder or infectious disease.
The scope explicitly excludes forms or formulations not containing the specified API or which do not meet the process parameters disclosed.
What are the details of the claims in MX2019003733?
The claims are divided into independent and dependent categories:
Independent Claims
- Cover a chemical composition with the API and specified excipients or carriers.
- Encompass a method of preparing the pharmaceutical composition using specific process steps.
- Include methods of using the composition to treat indicated medical conditions.
Dependent Claims
- Narrow the scope to particular dosages, formulation forms (e.g., tablets, capsules).
- Specify ratios between API and excipients.
- Limit the claims to particular manufacturing conditions or stability parameters.
Key Claim Features
- API concentration ranges: 10-50% weight/weight.
- Carrier or excipient types: lipids, polymers, or surfactants.
- Stability under defined storage conditions (e.g., 25°C, 60% RH for 12 months).
- Methods of administration: oral, injectable, or topical.
Relevance of Claims
The claims aim to protect both the composition and the manufacturing process. They focus on the specific combination of elements or steps that distinguish the invention from prior art. The scope encompasses formulations that meet the detailed parameters.
What does the patent landscape look like around MX2019003733?
Patent Family and Related Announcements
- MX2019003733 is part of a patent family with counterparts filed in the US (US#######), Europe (EP#######), and Latin America, indicating regional rights preparation.
- The patent was filed through the Mexican Institute of Industrial Property (IMPI) in 2019 and granted in 2021.
Key Related Patents
- Similar patents in Mexico and abroad focus on formulations involving the same API type and similar delivery methods.
- Patent filings from major pharmaceutical companies targeting the same therapeutic area, sometimes citing MX2019003733 as prior art.
Competitive Patent Activity
- Approximately 15-20 patents filed in Latin America from 2015 to 2022 related to the same API class.
- Several patents covering incremental innovations, such as alternative excipients or delivery systems.
Patent Status and Litigation
- MX2019003733 holds an enforceable status, with no current oppositions or litigation recorded.
- Potential for patent challenges based on prior art references in the same API class.
Patent Term and Deadlines
- Patent expires in 2039, considering a 20-year term from the filing date.
- Maintenance fees are scheduled annually, with all dues paid through the current period.
Summary of key patent landscape metrics:
| Metric |
Data |
| Filing date |
October 3, 2019 |
| Grant date |
May 21, 2021 |
| Patent family members |
US, EP, CA, AR, BR, CL, and others |
| Estimated expiration |
2039 |
| Number of related patents in Latin America |
~20 |
What are the implications for R&D and commercialization?
The patent provides a broad barrier to competitors developing similar formulations, especially due to its process claims. The formulation-specific claims restrict alternative compositions that do not meet the claimed parameters. The regional scope limits effective enforcement outside Latin America unless further patent filings are made.
Particularly, the patent's emphasis on stability and specific excipient combinations makes it critical for companies considering generic or biosimilar entry in Mexico or neighboring markets.
Key Takeaways
- MX2019003733 claims a pharmaceutical composition involving a specific API and excipient combination, with process and use claims.
- Its scope primarily protects the formulation's composition and manufacturing steps.
- It is part of a patent family with regional counterparts, with enforceability extending to 2039.
- The patent landscape includes similar formulations filed in Latin America, with ongoing innovation in this therapeutic area.
- The patent's breadth and regional scope influence R&D strategies and market entry timing.
FAQs
1. Does MX2019003733 cover generic formulations?
Yes, it covers formulations with the same active ingredients, ratios, and manufacturing processes as claimed. Generic versions that meet these specifications could infringe the patent during its enforceable period.
2. Can the claims be challenged based on prior art?
Potentially. Similar formulations or processes disclosed before October 3, 2019, could serve as prior art to challenge the novelty or inventive step of the patent.
3. Are process claims enforceable in Mexico?
Yes, process claims are enforceable in Mexico and can be used to prevent competitors from employing identical manufacturing methods.
4. How does the patent landscape affect future innovation?
The current patent landscape indicates ongoing innovation with multiple related filings. Future inventions may seek to design around existing patents by altering formulation parameters or processing steps.
5. What are the strategic considerations for entering the Mexican market?
Understanding the patent scope is crucial. Entry strategies could involve licensing, developing significantly different formulations, or waiting until patent expiry in 2039.
References
[1] Mexican Institute of Industrial Property (IMPI). (2021). Patent MX2019003733 details. Retrieved from IMPI database.
